Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Phase 4

Completed

• Conditions: Proliferative Diabetic Retinopathy
• Interventions: Drug: Bevacizumab; Other: sham

• Registration Number: NCT01025934
• Lead Sponsor: University of Campania "Luigi Vanvitelli"

Brief Summary

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Status Verified: 2009-12
• Study First Submitted: 2009-12-03
• Study First Submitted QC: 2009-12-03
• Last Update Submitted: 2009-12-03
• Study First Posted: 2009-12-04
• Last Update Posted: 2009-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• vitreous haemorrhage
• tractional retinal detachment
• active proliferative diabetic retinopathy.

Read More

Exclusion Criteria

• neovascular glaucoma
• cataract
• combined traction and rhegmatogenous RD

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
7 days	Bevacizumab	-
20 days	Bevacizumab	-
sham	sham	-